Thulium fiber laser versus holmium laser for ureteroscopic management of ureteral stones: a meta-analysis of randomized controlled trials
Abstract
Ureteroscopic laser lithotripsy is a standard treatment for ureteral stones. The holmium (Ho) laser is the long-standing reference device, while the thulium fiber laser (TFL) offers faster ablation and less retropulsion. However, randomized evidence comparing the two lasers specifically for ureteral stones remains uncertain. This meta-analysis followed the PRISMA 2020 statement and the Cochrane Handbook. PubMed, Scopus, Web of Science, and the Cochrane Library were searched from inception to March 2026. Randomized controlled trials directly comparing TFL with Ho for ureteral stones were included. Risk of bias was assessed with RoB 2 and certainty of evidence with GRADE. Five trials (maximum n≤579; 288 TFL, 291 Ho) were included. Stone-free rate did not show a significant difference (RR 1.04, 95% CI 1.00 to 1.08). TFL significantly shortened lasering time (MD â'4.39 min) and total operation time (MD â'5.76 min) and reduced severe retropulsion (RR 0.07). Mucosal injury was more frequent with TFL (RR 2.42). Hospital stay, ablation rate, laser energy, endoscopic view, and ureteric perforation were comparable. The certainty of evidence was low to very low. TFL and Ho achieve similar stone-free rates. TFL was associated with shorter operative and lasing times and less severe retropulsion but might increase the risk of mucosal injury. Laser choice should reflect clinical context, availability, and surgeon preference.